Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia (NCT03834961)

🧪 Interventions in This Study

• Larotrectinib Sulfate (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (80 Sites)

Showing the first 25 of 80 sites.

• Children's Hospital of Alabama — Birmingham, Alabama
• Arkansas Children's Hospital — Little Rock, Arkansas
• Kaiser Permanente Downey Medical Center — Downey, California
• Children's Hospital Los Angeles — Los Angeles, California
• Kaiser Permanente-Oakland — Oakland, California
• Children's Hospital of Orange County — Orange, California
• UCSF Medical Center-Mission Bay — San Francisco, California
• Children's Hospital Colorado — Aurora, Colorado
• Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center — Denver, Colorado
• Yale University — New Haven, Connecticut
• Alfred I duPont Hospital for Children — Wilmington, Delaware
• MedStar Georgetown University Hospital — Washington D.C., District of Columbia
• Children's National Medical Center — Washington D.C., District of Columbia
• Broward Health Medical Center — Fort Lauderdale, Florida
• Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
• University of Florida Health Science Center - Gainesville — Gainesville, Florida
• Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
• University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
• Nicklaus Children's Hospital — Miami, Florida
• Nemours Children's Hospital — Orlando, Florida
• Saint Joseph's Hospital/Children's Hospital-Tampa — Tampa, Florida
• Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
• Kapiolani Medical Center for Women and Children — Honolulu, Hawaii
• Saint Luke's Cancer Institute - Boise — Boise, Idaho
• Saint Jude Midwest Affiliate — Peoria, Illinois

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Central Nervous System Neoplasm

• Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System — Portland, Oregon
• Cerebrospinal Fluid Biomarkers for Brain Tumors — Rochester, Minnesota
• Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology — Houston, Texas

Explore by condition: All Central Nervous System Neoplasm clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.